NCT05113537 2026-04-13
UPLIFT
University of California, San Francisco
Phase 1/2 Recruiting
Clinical Trials
31 trialsNCT06303713 2026-04-08
LuCarbo - a Study of 177Lu-PSMA-617 Plus Carboplatin in Metastatic Castrate-resistant Prostate Cancer
Dana-Farber Cancer Institute
Phase 1 Active not recruiting
NCT05079698 2026-04-07
A Study of Stereotactic Body Radiotherapy and 177Lu-PSMA-617 for the Treatment of Prostate Cancer
Memorial Sloan Kettering Cancer Center
Phase 1 Active not recruiting
NCT06632977 2026-04-07
PREDICT
Alliance for Clinical Trials in Oncology
Phase 2 Recruiting
NCT07054346 2026-04-01
LUTACT
University of California, San Francisco
Phase 1 Recruiting
NCT04886986 2026-03-31
Phase I Study of 225Ac-J591 Plus 177Lu-PSMA Small Molecule for Progressive Metastatic Castration Resistant Prostate Cancer
Weill Medical College of Cornell University
Phase 1 Active not recruiting
NCT06389097 2026-03-30
(SEEtoTREAT)
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Recruiting
NCT06526299 2026-03-24
Low PSMA SUV Boost (LPS-Boost): Intensified 177Lu-PSMA-617 Treatment for Patients With Metastatic Castrate-Resistant Prostate Cancer With Low PSMA Expressing Disease
University of Washington
Phase 2 Recruiting
NCT07145177 2026-03-23
177Lu-PSMA-617 With Liver Directed Therapy in Metastatic Castration Resistant Prostate Cancer
University of California, San Francisco
Phase 1 Recruiting
NCT06288113 2026-03-13
Re-treatment With 177Lu-PSMA-617 for the Treatment of Metastatic Castration-Resistant Prostate Cancer, RE-LuPSMA Trial
Jonsson Comprehensive Cancer Center
Phase 2 Recruiting
NCT06216249 2026-03-10
Phase 2 Randomized Trial of Flexible Dosing Schedule of 177Lu-PSMA-617 for the Treatment of Metastatic Castration-Resistant Prostate Cancer (FLEX-MRT)
Jonsson Comprehensive Cancer Center
Phase 2 Recruiting
NCT04443062 2026-02-27
Bullseye
Radboud University Medical Center
Phase 2 Completed
NCT06145633 2026-01-28
Vorinostat and 177Lu-PSMA-617 for the Treatment of PSMA-Low Metastatic Castration-Resistant Prostate Cancer
Fred Hutchinson Cancer Center
Phase 2 Recruiting
NCT07219147 2026-01-28
177^Lu-PSMA-617 in Combination With Sipuleucel-T for the Treatment of Metastatic Castration-Resistant Prostate Cancer
City of Hope Medical Center
Phase 1 Recruiting
NCT05766371 2025-12-30
Pembrolizumab Plus 177Lu-PSMA-617 in Patients With Castration Resistant Prostate Cancer
University of California, San Francisco
Phase 2 Recruiting
NCT05162573 2025-12-10
PROQURE-1
The Netherlands Cancer Institute
Phase 1 Completed
NCT06574880 2025-11-24
STARLiT
Case Comprehensive Cancer Center
Phase 1/2 Recruiting
NCT07200830 2025-10-01
Testing Different Dosing Schedules of the Anti-cancer Drug, Lutetium 177Lu PSMA RLT and Its Effect on Patients With Advanced Prostate Cancer, RECIPROCAL Trial
Alliance for Clinical Trials in Oncology
Phase 3 Not yet recruiting
NCT03042468 2025-09-17
Phase I Dose-escalation Study of Fractionated 177Lu-PSMA-617 for Progressive Metastatic CRPC
Weill Medical College of Cornell University
Phase 1/2 Active not recruiting
NCT06200103 2025-09-11
Schedule De-Escalation of 177Lu-PSMA-617 for the Treatment of Metastatic Castrate Resistant Prostate Cancer
Mayo Clinic
Phase 2 Recruiting
NCT06738303 2025-08-27
CATCH-177
Case Comprehensive Cancer Center
Phase 2 Recruiting
NCT06972628 2025-05-15
Treatment of Patients With Progressive mCRPC With 177Lu-PSMA-617
Excel Diagnostics and Nuclear Oncology Center
Phase 2 Recruiting
NCT06461689 2025-03-04
PROLUT
Central Hospital, Nancy, France
Completed
NCT03805594 2025-02-25
177Lu-PSMA-617 and Pembrolizumab in Treating Patients With Metastatic Castration-Resistant Prostate Cancer
University of California, San Francisco
Phase 1 Completed
NCT06449781 2025-02-10
PSMA-ADJUVO
Maria Sklodowska-Curie National Research Institute of Oncology
Phase 2 Recruiting
NCT04430192 2024-11-08
LuTectomy
Peter MacCallum Cancer Centre, Australia
Phase 1/2 Active not recruiting
NCT06329830 2024-09-19
LUNAAR
Baptist Health South Florida
Phase 1/2 Withdrawn
NCT05150236 2023-12-15
ANZUP2001
Australian and New Zealand Urogenital and Prostate Cancer Trials Group
Phase 2 Unknown
NCT03392428 2022-06-13
TheraP
Australian and New Zealand Urogenital and Prostate Cancer Trials Group
Phase 2 Completed
NCT03545165 2021-08-24
177Lu-J591 and 177Lu-PSMA-617 Combination for mCRPC
Weill Medical College of Cornell University
Phase 1/2 Terminated
NCT03828838 2019-11-14
Lutetium-177-PSMA-617 in Low Volume Metastatic Prostate Cancer
Radboud University Medical Center
Phase 1/2 Completed